Aromatase inhibitor-induced bone loss increases the progression of estrogen receptor-negative breast cancer in bone and exacerbates muscle weakness in vivo
Aromatase inhibitors (AIs) cause muscle weakness, bone loss, and joint pain in up to half of
cancer patients. Preclinical studies have demonstrated that increased osteoclastic bone
resorption can impair muscle contractility and prime the bone microenvironment to
accelerate metastatic growth. We hypothesized that AI-induced bone loss could increase
breast cancer progression in bone and exacerbate muscle weakness associated with bone
metastases. Female athymic nude mice underwent ovariectomy (OVX) or sham surgery and …
cancer patients. Preclinical studies have demonstrated that increased osteoclastic bone
resorption can impair muscle contractility and prime the bone microenvironment to
accelerate metastatic growth. We hypothesized that AI-induced bone loss could increase
breast cancer progression in bone and exacerbate muscle weakness associated with bone
metastases. Female athymic nude mice underwent ovariectomy (OVX) or sham surgery and …
[引用][C] Aromatase inhibitor-induced bone loss increases the progression of estrogen receptor-negative breast cancer in bone and exacerbates muscle weakness in …
LE Wright, AA Harhash, WM Kozlow, DL Waning…
以上显示的是最相近的搜索结果。 查看全部搜索结果